ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 498,02
0,10%
Dow Jones
42 635,20
0,00%
DAX
20 332,25
0,06%
Brent Oil
78,315
1,81%
Bitcoin
94 778,10
2,56%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. INVO BioScience Inc (INVO)

  7. INVO BioScience Inc (INVO) Actualités

INVO

INVO BioScience (INVO)

INVO BioScience Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:INVO
DateHeureSourceTitreSymboleSociété
24/10/202415h00GlobeNewswire Inc.NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular CarcinomaNASDAQ:INVOINVO BioScience Inc
22/10/202418h05Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:INVOINVO BioScience Inc
21/10/202415h00GlobeNewswire Inc.INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA BiosciencesNASDAQ:INVOINVO BioScience Inc
15/10/202415h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
14/10/202415h18GlobeNewswire Inc.INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)NASDAQ:INVOINVO BioScience Inc
14/08/202415h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INVOINVO BioScience Inc
14/08/202415h00GlobeNewswire Inc.INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDANASDAQ:INVOINVO BioScience Inc
21/05/202422h39Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:INVOINVO BioScience Inc
15/05/202422h15GlobeNewswire Inc.INVO Reports Record First Quarter 2024 Financial ResultsNASDAQ:INVOINVO BioScience Inc
17/04/202416h25AllPennyStocks.comMicro Cap Massively Bid Up Before Opening BellNASDAQ:INVOINVO BioScience Inc
16/04/202422h59GlobeNewswire Inc.INVO Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:INVOINVO BioScience Inc
06/02/202416h24Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:INVOINVO BioScience Inc
23/01/202414h00GlobeNewswire Inc.NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)NASDAQ:INVOINVO BioScience Inc
17/01/202414h00GlobeNewswire Inc.INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board DirectorsNASDAQ:INVOINVO BioScience Inc
16/01/202423h29Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:INVOINVO BioScience Inc
10/01/202422h46Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:INVOINVO BioScience Inc
28/12/202323h04Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:INVOINVO BioScience Inc
13/12/202323h08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:INVOINVO BioScience Inc
11/12/202314h00PR Newswire (US)NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood JournalNASDAQ:INVOINVO BioScience Inc
28/11/202315h00PR Newswire (US)INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementNASDAQ:INVOINVO BioScience Inc
24/11/202319h08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:INVOINVO BioScience Inc
13/11/202322h01PR Newswire (US)INVO Reports Record Third Quarter 2023 Financial ResultsNASDAQ:INVOINVO BioScience Inc
13/11/202315h23Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:INVOINVO BioScience Inc
13/11/202315h12Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:INVOINVO BioScience Inc
10/11/202315h00PR Newswire (US)NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending MergerNASDAQ:INVOINVO BioScience Inc
09/11/202322h40PR Newswire (US)INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase WarrantsNASDAQ:INVOINVO BioScience Inc
27/10/202315h00PR Newswire (US)Free Registration Is Now Open For Tribe Public's CEO and Q&A Presentation Webinar Event "Accelerating Biotech Value Creation" Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023NASDAQ:INVOINVO BioScience Inc
23/10/202313h30PR Newswire (US)INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science CompanyNASDAQ:INVOINVO BioScience Inc
11/10/202315h00PR Newswire (US)INVO to Participate in the Lytham Partners Fall 2023 Investor ConferenceNASDAQ:INVOINVO BioScience Inc
29/09/202322h05PR Newswire (US)INVO BIOSCIENCE ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF SHAREHOLDERSNASDAQ:INVOINVO BioScience Inc
 Showing the most relevant articles for your search:NASDAQ:INVO

Dernières Valeurs Consultées

EU
MC
Lvmh Moet Hennessy Louis...
EU
BEL20
Bel 20
EU
ORA
Orange
COIN
BTCUSD
Bitcoin
EU
RI
Pernod Ricard
NYSE
MRK
Merck
NASDAQ
GOOGL
Alphabet
NYSE
DIS
Walt Disney
EU
BNP
BNP Paribas
EU
GLE
Societe Generale
EU
SGO
Cie de SaintGobain
EU
CS
Axa
EU
RNO
Renault
COIN
ADAUSD
Cardano
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés